Article ; Online: The kinetics of SARS-CoV-2 viremia in COVID-19 patients receiving remdesivir.
2023 Volume 42, Issue 8, Page(s) 951–958
Abstract: Detection of SARS-CoV-2 RNA in serum, viremia, has been linked to disease severity and outcome. The kinetics of viremia in patients receiving remdesivir has not been thoroughly studied and could help predict treatment response and outcome. We ... ...
Abstract | Detection of SARS-CoV-2 RNA in serum, viremia, has been linked to disease severity and outcome. The kinetics of viremia in patients receiving remdesivir has not been thoroughly studied and could help predict treatment response and outcome. We investigated the kinetics of SARS-CoV-2 viremia and factors associated with baseline viremia, viral clearance and 30-day mortality in patients receiving remdesivir. An observational study including 378 hospitalised patients (median age 67 years, 67% male) sampled with serum SARS-CoV-2 RT-PCR within ± 24 h of initiation of remdesivir treatment. Baseline viremia was present in 206 (54%) patients with a median Ct value of 35.3 (IQR = 33.3-37.1). In patients with baseline viremia, the estimated probability of viral clearance was 72% by day 5. Ct values decreased significantly during remdesivir treatment for viremic patients, indicating an increase in viral load. In total, 44 patients (12%) died within 30 days, and mortality was significantly associated with viremia at baseline (OR = 2.45, p = 0.01) and lack of viral clearance by day 5 (OR = 4.8, p = < 0.01). Viral clearance was not associated with any individual risk factor. Viremia appears to be a prognostic marker before and during remedesivir treatment. The resolution of viremia was similar to patients not receiving remdesivir in other studies, and the decrease in Ct values during treatment questions the antiviral capacity of remdesivir in vivo. Prospective studies are warranted to confirm our findings. |
---|---|
MeSH term(s) | Humans ; Male ; Aged ; Female ; COVID-19 ; SARS-CoV-2 ; Kinetics ; Viremia/drug therapy ; RNA, Viral ; COVID-19 Drug Treatment ; Antiviral Agents/therapeutic use |
Chemical Substances | remdesivir (3QKI37EEHE) ; RNA, Viral ; Antiviral Agents |
Language | English |
Publishing date | 2023-05-27 |
Publishing country | Germany |
Document type | Observational Study ; Journal Article |
ZDB-ID | 603155-9 |
ISSN | 1435-4373 ; 0934-9723 ; 0722-2211 |
ISSN (online) | 1435-4373 |
ISSN | 0934-9723 ; 0722-2211 |
DOI | 10.1007/s10096-023-04627-4 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1732: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.